Clinical significance of urotensin 2 plasma level in patients diagnosed with prostate cancer.

249 Background: Urotensin-II is a small somatostatin-like cyclic peptide characterized by its potent vasoconstrictor activity. Urotensin-II (UT-II) and its receptor (UTR) have been shown to play a role in the formation of different epithelial cancers. To date, many studies have been reported in prostate cancer that provide genetic contributions with diagnostic, prognostic and therapeutic potential for carcinogenesis. However, the role of urotensin-II in prostate carcinogenesis has not yet been elucidated. There are several limitations to using PSA as a biomarker in prostate cancer follow-up. More accurate and specific biomarkers are needed to improve diagnosis and monitoring of prostate cancer. Our study aimed to reveal the clinical importance of plasma UT-2 level in metastatic prostate cancer patients and to investigate its correlation and prognostic importance with clinical parameters such as PSA level and pathological parameters such as Gleason Score. Methods: Patients who applied to İzmir Katip Celebi University Atatürk Training and Research Hospital Medical Oncology Polyclinic in 2023 were included in our study. The demographic information of the patients was scanned from the oncology file system and recorded. Measurements of plasma ÜT-2 level were made by a biochemistry specialist at İzmir Katip Celebi University Atatürk Training and Research Hospital Biochemistry Laboratory. For the ELISA method, Urotensin 2 ELISA (Elabscience lot no: E-EL-2047) kit was used in the Biotek (ELx800, USA) semi-automatic ELISA device. Results: A total of 147 patients, 100 metastatic and 47 control groups, were included in our study. No statistically significant difference was observed between the groups in terms of additional diseases that may be related to UT-2 level: Diabetes Mellitus, hypertension, peripheral artery disease, coronary artery disease, chronic renal failure and smoking characteristics (p>0.05). When the PT-2 level was compared between the de-novo and non-de-novo metastasis groups and the control groups, both metastasis groups had a higher average than the control groups (p = 0.004). The cut-off value for UT-2 was determined as 1.269 ng/mL. UT-2 sensitivity, specificity, positive predictive value and negative predictive value were found to be 81%, 53%, 79% and 57%, respectively. Conclusions: Today, studies are continuing rapidly to increase the efficiency of PSA and to find new tumor markers. In our study, UT-2 levels in metastatic prostate cancer patients were found to be statistically higher than other groups. This is the first study in the literature to study the UT-2 plasma level in prostate cancer, and UT-2 may be an important biomarker in predicting prognosis in prostate cancer.